Know Cancer

forgot password

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

Phase 2
18 Years
Not Enrolling
Relapsed Follicular Lymphoma

Thank you

Trial Information

A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE (Bortezomib) in Combination With Rituximab, Cyclophosphamide, and Prednisone With or Without Doxorubicin Followed by Rituximab Maintenance in Patients With Relapsed Follicular Lymphoma.

Inclusion Criteria:

- Male or female patient 18 years of age or older

- Pathological diagnosis of follicular lymphoma (any grade) or marginal zone lymphoma.
Patients with transformed follicular lymphoma are eligible, provided there has
previously been pathologic documentation of follicular lymphoma.

- Documented relapse or progression following prior antineoplastic therapy

- At least 1 measurable tumor mass that is greater than 1.5 cm in the long axis and
greater than 1.0 cm in the short axis that has not been previously irradiated, or has
grown since previous irradiation

- No clinically significant evidence of active central nervous system lymphoma

- Karnofsky performance status (KPS) ≥50 (equivalent to Eastern Cooperative Group
Oncology Group [ECOG] status ≤2)

Exclusion Criteria:

- Diagnosed or treated for a malignancy other than Non-Hodgkin's Lymphoma (NHL) within
2 years of first dose, or who were previously diagnosed with a malignancy other than
NHL and have any radiographic or biochemical marker evidence of malignancy. Patients
with prostate cancer who were treated with definitive radiotherapy who have a serum
prostate-specific antigen <1 ng/mL are not excluded. Patients are not excluded if
they have had basal cell or squamous cell carcinoma of the skin that was completely
resected, or any in situ malignancy that was adequately treated.

- Received any of the following treatments or procedures outside of the specified

- Prior treatment with VELCADE

- Prior treatment with a cumulative dose of doxorubicin of more than 100 mg/m2,
if assigned to Arm A (VELCADE-R-CAP)

- Antineoplastic (including unconjugated therapeutic antibodies and toxin
immunoconjugates), experimental, or radiation therapy within 3 weeks before Day
1 of Cycle 1

- Nitrosoureas within 6 weeks before Day 1 of Cycle 1

- Radioimmunoconjugates within 10 weeks before Day 1 of Cycle 1

- Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or
prior allogeneic stem cell transplant at any time

- Major surgery within 2 weeks before Day 1 of Cycle 1

Type of Study:


Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Number of Patients With Complete Response (CR)

Outcome Description:

Disappearance of all evidence of disease assessed by computed tomography (CT) and PET (position-emission tomography) according to the revised International Working Group (IWG) Criteria.

Outcome Time Frame:

30 weeks

Safety Issue:


Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Millennium Pharmaceuticals, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

September 2008

Completion Date:

March 2011

Related Keywords:

  • Relapsed Follicular Lymphoma
  • Lymphoma
  • Lymphoma, Follicular



Avera Cancer Institute Sioux Falls, South Dakota  57105
Marshfield Clinic Marshfield, Wisconsin  54449
New York Medical College Valhalla, New York  10595
Western Pennsylvania Cancer Institute Pittsburgh, Pennsylvania  15224
Great Plains Regional Medical Center North Platte, Nebraska  69101-6598
Southern Nevada Cancer Research Foundation Las Vegas, Nevada  89106
Jackson Oncology Associates, PLLC Jackson, Mississippi  39202
St. Joseph Mercy Hospital Pontiac, Michigan  48341-2985
Temple University Philadelphia, Pennsylvania  19140
Medical Oncology, LLC Baton Rouge, Louisiana  70808
Northern Utah Associates Ogden, Utah  84403
Allegheny-Singer Research Institute Pittsburgh, Pennsylvania  15212
Dartmouth Hitchcock Medical Center Lebanon, New Hampshire  03756
Gabrail Cancer Center Canton, Ohio  44718
San Juan Oncology Associates Farmington, New Mexico  87401
Hope Oncology Richardson, Texas  75080
Providence Saint Joseph Medical Center Burbank, California  91505-4866
Kalamazoo Hematology and Oncology Kalamazoo, Michigan  49048
Nebraska Hematology-Oncology, PC Lincoln, Nebraska  68506
Cancer Care Center, Inc. New Albany, Indiana  47150
NYU Clinical Cancer Center New York, New York  10016
Alexian Brothers Hospital Network Elk Grove Village, Illinois  60007
University of Tennessee Medical Center Knoxville, Tennessee  37920
Northwest Georgia Oncology Centers, PC Marietta, Georgia  30060
Cancer Center of Central Connecticut Southington, Connecticut  
Siouxland Hematology Oncology Associates Sioux City, Iowa  51101
Purchase Cancer Group Paducah, Kentucky  42002
Landmark Medical Center Woonsocket, Rhode Island  02895
Northwest Alabama Center, PC Muscle Shoals, Alabama  35661
Pacific Coast Hematology Oncology Medical Group Fountain Valley, California  92708
Loma Linda U Cancer Center Loma Linda, California  92354
Desert Hematology Medical Group, Inc. Rancho Mirage, California  92270
Ocala Cancer Institute Ocala, Florida  34471
Southern Illinois Hematology Oncology Centralia, Illinois  62801
Clintell, Inc. Skokie, Illinois  60077
Hutchinson Clinic Hutchinson, Kansas  67502
St. Louis Cancer Care, LLP Chesterfield, Missouri  63017
Interlakes Foundation Rochester, New York  14623
Oklahoma Oncology and Hematology, PC Oklahoma City, Oklahoma  73112
Marshall University Huntington, West Virginia  25701
West Virginia University Health Science Center Morgantown, West Virginia  26505